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abstract
PURPOSE Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL)
are of considerable interest. We investigated cHL prognosis in the era of contemporary treatment at different
milestones during the follow-up.
PATIENTS AND METHODS On the basis of a Nordic cohort of 2,582 patients diagnosed at ages 18 to 49 years
between 2000 and 2013, 5-year relapse risks and 5-year restricted losses in expectation of lifetime were
estimated for all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36
(EFS36) or 60 (EFS60) months. The median follow-up time was 9 years (range, 2.9 to 16.8 years).
RESULTS The 5-year overall survival was 95% (95% CI, 94% to 96%). The 5-year risk of relapse was 13.4%
(95% CI, 12.1% to 14.8%) overall but decreased to 4.2% (95% CI, 3.8% to 4.6%) given that patients reached
EFS24. Relapse risk for patients treated with six to eight courses of bleomycin, etoposide, doxorubicin, cy-
clophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) was comparable to that of patients
treated with six to eight courses of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) despite more
adverse risk criteria among patients treated with BEACOPP. Both from diagnosis and if EFS24 was reached,
the losses in expectation of lifetime during the following 5 years were small (from diagnosis, 45 days [95% CI,
35 to 54 days] and for patients who reached EFS24, 13 days [95% CI, 7 to 20 days]). In stage-stratified
analyses of 5-year restricted loss in expectation of lifetime, patients with stages I to IIA disease had no
noteworthy excess risk of death after they reached EFS24, whereas risk remainedmeasurable for patients with
stages IIB to IV cHL.
CONCLUSION Real-world data on young patients with cHL from the Nordic countries show excellent outcomes.
The outlook is particularly favorable for patients who reach EFS24, which supports limited relapse-oriented
clinical follow-up.
J Clin Oncol 37:703-713. © 2019 by American Society of Clinical Oncology
INTRODUCTION
The treatment of classic Hodgkin lymphoma (cHL) is
one of the great success stories of modern oncology.1
The introduction of combined modality treatment of
limited-stage disease and effective multiagent che-
motherapy regimens for advanced-stage disease were
paradigm shifts that led to high cure rates across all
disease stages.2-6 The first peak in the bimodal in-
cidence pattern of Hodgkin lymphoma (HL) appears
around the age of 20 to 30 years; cHL differs from
many other malignancies in that a large fraction of the
patients are young, otherwise healthy, and fit enough
to receive full-dose curative-intent treatment.7 Favor-
able short-term outcomes in a young patient group
with long residual life expectancy have led to a fo-
cus on reducing short- and long-term toxicity without
compromising treatment efficacy.8-10 At present, car-
diovascular disease, fatigue, infertility and risk of
secondary malignancies are some of the major health
issues faced by patients with HL.2,7,11-15 Replacement
of vincristine, nitrogen mustard, procarbazine hydro-
chloride, and prednisone (MOPP) chemotherapy with
the less toxic regimen of doxorubicin, bleomycin,
vinblastine, and dacarbazine (ABVD) and improved
radiotherapy (RT) techniques are anticipated to
reduce late toxicities substantially in the coming
years.16,17 These modified treatment options have led
to increases in relative survival for Swedish patients
ASSOCIATED
CONTENT
Data Supplement
Author affiliations
and support
information (if
applicable) appear
at the end of this
article.
Accepted on
December 17, 2018
and published at jco.
org on February 6,
2019: DOI https://doi.
org/10.1200/JCO.18.
01652
Volume 37, Issue 9 703
Downloaded from ascopubs.org by Royal Library on September 15, 2020 from 130.226.230.027
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
with HL diagnosed before age 65 years.18 A recent study of
1,402 patients with cHL diagnosed in British Columbia
(including some treated with MOPP combinations) docu-
mented increased standardized mortality ratios in cHL,
even for patients in ongoing remission for many years.19
This could indicate that late toxicities still have an impact on
residual life expectancy despite efforts to reduce serious
long-term toxicities.19 In this Nordic population-based study
of patients with cHL age 18 to 49 years and diagnosed
during 2000 to 2013, we compared the survival with that of
a healthy background population and explored the evo-
lution of the relapse risk for patients in ongoing remissions
at different milestones.
Study Population and Data Sources
Patients were identified using national and regional reg-
isters and databases.20-22 The Danish cohort was extracted
from the nationwide Danish Lymphoma Register (LYFO),
which includes clinical and outcome data. In a recent
quality assessment, LYFO was shown to have a coverage of
95% of all Danish patients with lymphoma.23 The Swedish
cohort consisted of patients included in the Swedish
Cancer Register, which covers nearly 100% of all Swedish
patients with cancer, for whom clinical information was
retrievable from the Swedish Lymphoma Register (SLR).24,25
The Cancer Registry of Norway covers approximately 99%
of all cancer occurrences in Norway and was used to
identify patients with HL who were covered by the Southern
and Eastern Regional Health Authority/Oslo University
Hospital.22 For the Norwegian patient cases, clinical data
were extracted from the clinical lymphoma database at
Oslo University Hospital (CLDOUH), which covers ap-
proximately 55% of the Norwegian population, and were
supplemented by local review of medical files in cases of
missing data. Complete follow-up for all patients was en-
sured by a merge with the national population registers,
which contain accurate information on vital statuses for
all citizens of Denmark, Sweden, and Norway.23,24 The
follow-up end dates were November 16, 2016, October
31, 2015, and December 15, 2016, for Denmark, Swe-
den, and Norway, respectively. Patients who experience a
relapse/progression are reported to LYFO, the SLR, or the
CLDOUH. To identify missing relapses, LYFO is merged
regularly with the Danish National Pathology Registry,
which includes biopsy-confirmed relapses.26 Patients who
receive chemotherapy or RT within 9 months post di-
agnosis are automatically signaled to the treating physi-
cian to be reviewed for possible relapse. To identify
unreported relapses in the Swedish data, retrospective
review of medical records was performed in three of six
health care regions, and all performed stem-cell trans-
plantations were identified in the National Patient Reg-
ister, as previously described.21,27 In Norway, treatment of
cHL is fully centralized to the regional hospital, and
relapses/progressions are prospectively registered in
CLDOUH. In this study, stable or progressive disease at
the time of response evaluation after first-line treatment
was included in our definition of progression.
Inclusion criteria for this study were as follows: newly di-
agnosed cHL in 2000 to 2013; treated with chemotherapy
alone or combination therapy with involved-field or
involved-node RT; and age of 18 to 49 years at diagnosis.
Treatment information and clinicopathologic variables were
retrieved directly from LYFO, SLR, and CLDOUH (Table 1).
Patients with limited-stage disease were preferably treated
with two to four courses of ABVD (four courses if one or
more of the following risk factors were present: erythrocyte
sedimentation rate . 50, bulky disease, involvement of
three or more lymph node regions) and 20 to 30 Gy of
involved-field/-node RT. Patients with advanced-stage
disease were treated with six to eight courses of ABVD,
bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, prednisone (BEACOPP-14), or
escalated BEACOPP (eBEACOPP); the two BEACOPP
treatments were mainly administered to patients with in-
ternational prognostic scores greater than 2. Consolidative
RT to isolated areas may have been used after full che-
motherapy and was aimed at extranodal disease sites or
residual masses of uncertain significance in the pre-
positron emission tomography (PET)/computed tomogra-
phy (CT) era and single residual fluorodeoxyglucose-avid
lesions when PET/CT became available. Between 2008
and 2012, a limited number of patients were included in the
Response Adapted Therapy in Advanced Hodgkin. Lym-
phoma (RATHL) trial and received PET-guided treatment
with two courses of ABVD followed by random assign-
ment to four additional courses of doxorubicin, vinblastine,
and dacarbazine or ABVD if they had PET-negative disease
and to BEACOPP-14/eBEACOPP if they had PET-positive
disease.10
Statistical Analysis
Overall survival (OS) was defined as time from cHL di-
agnosis until death as a result of any cause. Event-free
survival (EFS) was defined as the time from diagnosis to
death, or progression (evaluated at the response evaluation
after first-line treatment) or relapse, whichever came first.
Because of the structure of the databases, we were unable
to determine whether consolidative RT was administered as
part of planned combined-modality treatment or to areas of
disease with suboptimal response to chemotherapy. Thus,
we did not include consolidative RT in our definition of EFS.
Patients who did not experience an event were censored at
the end of follow-up. Exact dates of the response evaluation
after first-line treatment were not available in the Swedish
and Norwegian cohorts, and response evaluations were
assumed to have happened 243 days after diagnosis,
which was the median time from diagnosis to response
evaluation after first-line treatment in the Danish cohort.
Sensitivity analyses with respect to the imputed time were
performed. Survival curves were estimated with the Kaplan-
Meier estimator.
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TABLE 1. Clinical Characteristics of Danish, Swedish, and Norwegian Patients With Classic Hodgkin Lymphoma Age 18 to 49 Years at Diagnosis
Characteristic
No. (%) of Patients
Denmark (n = 863) Sweden (n = 1,236) Norway (n = 483) Combined (N = 2,582)
Age at diagnosis, years
18-34 505 (58.5) 849 (68.7) 314 (65.0) 1,668 (64.6)
35-49 358 (41.5) 387 (31.3) 169 (35.0) 914 (35.4)
Sex
Female 394 (45.7) 620 (50.2) 225 (46.6) 1,239 (48.0)
Male 469 (54.3) 616 (49.8) 258 (53.4) 1,343 (52.0)
Calendar period
2000-2005 344 (39.9) 510 (41.3) 195 (40.4) 1,049 (40.6)
2006-2013 519 (54.3) 726 (58.7) 288 (59.6) 1,533 (59.4)
Ann Arbor stage
I 128 (14.8) 122 (9.9) 54 (11.2) 304 (11.8)
II 405 (46.9) 678 (54.9) 223 (46.2) 1,306 (50.6)
III 184 (21.3) 217 (17.6) 89 (18.4) 490 (19.0)
IV 139 (16.1) 206 (16.7) 116 (24.0) 461 (17.9)
Missing 7 (0.8) 13 (1.1) 1 (0.2) 21 (0.8)
Limited (IA-IIA) 362 (41.9) 554 (44.8) 191 (39.5) 1,107 (42.9)
Advanced (IIB-IV) 494 (57.2) 669 (54.1) 291 (60.2) 1,454 (56.3)
Bone marrow involvement
No 816 (94.6) 603 (48.8) 442 (91.5) 1,861 (72.1)
Yes 47 (5.4) 53 (4.3) 31 (6.4) 131 (5.1)
Missing 0 (0.0) 580 (46.9) 10 (2.1) 590 (22.9)
Extranodal disease
No 678 (78.6) 603 (48.8) 341 (70.6) 1,622 (62.8)
Yes 185 (21.4) 236 (19.1) 131 (27.1) 552 (21.4)
Missing 0 (0.0) 397 (32.1) 11 (2.3) 408 (15.8)
Treatment*
Chemotherapy 2-4 and RT 290 (33.6) 352 (28.6) 159 (32.9) 801 (31.0)
Chemotherapy 2-4 no RT 21 (2.4) 34 (2.8) 16 (3.3) 71 (2.7)
Chemotherapy 6-8 and RT 176 (20.4) 119 (9.6) 61 (12.6) 356 (13.8)
Chemotherapy 6-8 no RT 277 (32.1) 471 (38.1) 244 (50.5) 992 (38.4)
Missing RT status 1 (0.1) 256 (20.7) 3 (0.6) 260 (10.1)
RT and chemotherapy 98 (11.4) 0 (0) 0 (0.0) 98 (3.8)
Other 0 (0.0) 4 (0.3) 0 (0.0) 4 (0.2)
Chemotherapy†
ABVD 2-4 309 (35.8) 366 (29.6) 171 (35.4) 846 (32.8)
ABVD 6-8 357 (41.4) 400 (32.4) 190 (39.3) 947 (36.7)
BEACOPP 6-8 88 (10.2) 168 (13.6) 45 (9.3) 301 (11.7)
Unspecified chemotherapy‡ 0 (0.0) 245 (19.8) 3 (0.6) 248 (9.6)
(continued on following page)
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Progression/relapse risk was estimated using the Aalen-
Johansen estimator with death as competing risk. The
evolution of the 5-year relapse risk from diagnosis and
conditional on reaching EFS milestones was also in-
vestigated by use of logistic regression models with
progression/relapse within 5 years after the studied mile-
stone as outcome. The censoring and competing risk
(death without disease progression) were accounted for by
relying on pseudo-observations (Data Supplement).28
The 5-year restricted loss in expectation of lifetime (5y-
RLEL) was defined as the numeric difference in the number
of days a healthy person and a patient are expected to
survive within the next 5 years.29 Estimates were obtained
for all patients and for patients who reached 12 months
(EFS12), 24 months (EFS24), 36 months (EFS36) or 60
months (EFS60) of survival. The analyses were based on
pseudo-value methodology (Data Supplement).30
All analyses were performed both in a stratifiedmanner and
by use of multivariable models. An analysis of the un-
restricted loss in expectation of lifetime is reported in the
Data Supplement.
The pseudo-value (pseudo and geepack packages) ana-
lyses were done in R (version 3.4.4). In case of missing
information, available-case analyses were performed. The
study was approved by the Danish Data Protection Agency
(internal ID No. 2016-93) and relevant review boards in
Stockholm (Sweden) and Oslo (Norway). All data were
anonymized for analysis.
RESULTS
Demographic Characteristics and OS
In total, 2,582 patients with cHL were included (Denmark,
n = 863; Sweden, n = 1,236; Norway, n = 483; Table 1).
Among those with available data on chemotherapy type, the
majority received ABVD treatment (n = 1,793), and a
fraction (n = 301) received BEACOPP-14 or eBEACOPP
(Table 1). Patients with advanced-stage disease who were
treated with BEACOPP were more often male and more
often had involvement of bone marrow and/or other
extranodal sites (stage IV) compared with those who had
advanced-stage disease but were treated with six to eight
cycles of ABVD (Data Supplement). More patients were
diagnosed with advanced-stage disease in 2006 to 2013
than in the earlier inclusion period (2000 to 2005; Data
Supplement). The median follow-up time was 9 years
(range, 2.9 to 16.8 years).31 The 5-year OS was 95.2%
(95% CI, 94.4% to 96.1%), and estimates were similar by
country (Fig 1).
Relapse Risk in Clinical Subgroups
The overall 5-year progression/relapse risk was 13.4%
(95% CI, 12.1% to 14.8%) from diagnosis, and estimates
were similar by country (Data Supplement). For patients
who reached the EFS24 and EFS60 milestones, 5-year
relapse risks after the milestone and onward were 4.2%
(95%CI, 3.8% to 4.6%) and 1.3% (95%CI, 1.0% to 1.6%),
respectively (Fig 2). The 5-year relapse risk for patients with
advanced-stage disease was twice as high as for patients
with limited-stage disease from diagnosis, but the differ-
ence decreased substantially among patients who reached
later EFS milestones and was minimal after EFS36 (ad-
vanced stage, 2.5% [95% CI, 2.1% to 2.9%] v limited
stage, 2.0% [95% CI, 1.6% to 2.4%]) and after EFS60
(advanced stage, 1.5% [95% CI, 1.1% to 2.0%] v limited
stage, 1.1% [95% CI, 0.7% to 1.6%]). Male patients and
patients diagnosed between 2000 and 2005 had a higher
5-year relapse risk than female patients and patients di-
agnosed between 2006 and 2013, respectively (Fig 2).
TABLE 1. Clinical Characteristics of Danish, Swedish, and Norwegian Patients With Classic Hodgkin Lymphoma Age 18 to 49 Years at Diagnosis (continued)
Characteristic
No. (%) of Patients
Denmark (n = 863) Sweden (n = 1,236) Norway (n = 483) Combined (N = 2,582)
MOPP/MOPP-ABV 2-4§ 2 (0.2) 7 (0.6) 0 (0.0) 9 (0.3)
MOPP/MOPP-ABV 6-8§ 8 (0.9) 5 (0.4) 3 (0.6) 16 (0.6)
Otherk 99 (11.5) 45 (3.6) 71 (14.7) 215 (8.3)
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, prednisone; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; MOPP/ABV, mechlorethamine, vincristine,
procarbazine, prednisone/doxorubicin, bleomycin, and vinblastine; RT, radiotherapy.
*Chemotherapy courses are designated by numeric ranges (eg, two to four courses represented by Chemotherapy 2-4). For RT and chemotherapy group,
cycles were unspecified.
†Patients who received one course of chemotherapy were put into the group with two to four courses of treatment (eg, ABVD 2-4), and patients who
received five courses were put into the group with six to eight courses (eg, ABVD 6-8 or BEACOPP 6-8).
‡ABVD and BEACOPP regimens were the recommended treatments during the study period, but the exact chemotherapy was not specified in the register
data.
§Treatments were two to four courses (MOPP/MOPP-ABV 2-4) or six to eight courses (MOPP/MOPP-ABV 6-8).
kOther includes patients who changed treatment plan according to the results of an interim positron emission tomography scan, mainly patients included in
the RATHL (Response Adapted Therapy in Advanced Hodgkin. Lymphoma) trial.
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Relapse risks were similar for patients with advanced-stage
disease who were treated with six to eight cycles of ABVD
and those with advanced-stage disease who were treated
with six to eight cycles of BEACOPP at all analyzed time
points despite the fact that the BEACOPP-treated group
displayed more high-risk features (Fig 2; Data Supple-
ment). The 5-year relapse risk was similar for patients who
were 18 to 34 or 35 to 49 years old at diagnosis, but, after
EFS60, the group of patients age 35 to 49 years had a
slightly higher risk of relapse (35 to 49 years, 2.3% [95%CI,
1.6% to 3.1%] v 18 to 34 years, 0.8% [95% CI, 0.1% to
1.2%]). Sensitivity analyses with respect to the imputed
response evaluation data led to changes in the estimated
relapse risk of less than 1% for the period between di-
agnosis and EFS12; the changes observed from EFS12
onward were negligible (Data Supplement).
Loss of Expectation of Lifetime
5y-RLEL was computed as an absolute measure of loss of
lifetime in a 5-year period. Within the first 5 years post-
diagnosis, patients with HL were expected to live 45 days
(95% CI, 35 to 54 days) less than the background pop-
ulation (Fig 3). For patients who reached the EFS24
milestone, this difference was 13 days (95% CI, 7 to
20 days). For patients who reached the EFS60 milestone,
the subsequent 5y-RLEL was 8 days (95%CI, 2 to 14 days).
We observed that the impact of baseline high-risk features
on the 5y-RLEL estimates decreased for patients in ongoing
remission. As an example, 5y-RLEL estimates from di-
agnosis were 67 days (95% CI, 52 to 82 days) for patients
with advanced-stage disease and 14 days (95% CI, 5 to
22 days) for patients with limited-stage disease, whereas
the corresponding estimates for patients who reached
EFS24 were 23 days (95% CI, 13 to 34 days) for advanced-
stage disease and 2 days (95%CI,24 to 7 days) for limited-
stage disease. The 5y-RLEL differences when patients were
stratified by sex (female, 35 days [95% CI, 23 to 46 days]
v male, 54 [95% CI, 39 to 68 days]), by diagnosis year
(2000 to 2005, 46 days [95% CI, 31 to 60 days] v 2006 to
2013, 44 days [95% CI, 32 to 56 days]), by age (18 to 34
years, 39 days [95% CI, 29 to 50 days] v 35 to 49 years,
54 days [95% CI, 36 to 72 days]), and by treatment for
advanced-stage patients (six to eight courses of ABVD,
45 days [95% CI, 29 to 62 days] v six to eight courses of
BEACOPP, 67 days [95% CI, 35 to 99 days]) were less
pronounced.
Multivariable models for the 5y-RLEL and relapse risk and
an unrestricted loss in expectation of lifetime analysis
showed similar results with respect to the effects of the
different risk factors and confirmed the favorable disease
outlook for patients who reached the EFS24 and EFS60
milestones (Figs 4 and 5; Data Supplement).
DISCUSSION
This study was based on patients with cHL who were
treated in a real-world clinical setting and used population-
wide registers from the Nordic countries. We focused
exclusively on young patients, who are typically healthy
and fit enough to receive curative-intent therapy, and
found that outcomes were excellent with only a minimal
relapse risk and a low restricted loss in expectation of
lifetime for patients who reached EFS24. Interestingly, the
effect on relapse risk of disease stage, one of the most
widely recognized prognostic factors in cHL, disappeared
over time and became negligible after EFS36. We believe
that conclusions drawn from this study are of major im-
portance to patients with cHL and their families as well as
to health care providers who manage the disease and
follow-up.
We observed a consistent low risk of relapse for patients
with cHL who reached the EFS24 and, in particular, EFS60
milestones. Five-year relapse risks of 5% or lower were
observed in nearly all subgroups of patients who reached
EFS24, which suggests that those patients can be com-
forted and reassured that their future relapse risk is low. For
patients with limited-stage disease, the loss in life expec-
tancy after EFS24 within the next 5 years was nearly zero,
which suggests that this group of cHL survivors are not at
increased short-term risk of death compared with people of
similar age and sex without cHL. The 5y-RLEL and 5-year
relapse risk estimates were lower for patients diagnosed
between 2006 and 2013 than for those diagnosed between
2000 and 2005. However, given the potential stage mi-
gration (Data Supplement), this effect should be consid-
ered in light of the use of more accurate staging methods
that have led to more adequate treatment of some patients
in addition to other general treatment improvements.32 The
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large reduction in relapse risk and loss of expectation of
lifetime observed already after EFS24 confirm that events
mainly occur in the first 2 years after therapy. This is
consistent with results from the study by Hapgood et al19
that involved a cohort of 1,402 patients with cHL from
British Columbia, Canada. In that study, the 5-year relapse
risk of 18.1% decreased to 5.6% for patients who reached
EFS24. In general, the 5-year relapse risks tended to be
lower in our study; most importantly, our 5-year relapse
risk from the time of diagnosis was lower than that
reported by Hapgood et al19 (13.4% in this study v 18.1%
in that of Hapgood et al19). This is likely partially explained
by the inclusion in the study by Hapgood at al19 of el-
derly patients up to age 69 years at diagnosis, who had a
higher relapse risk. Furthermore, Hapgood at al19 in-
cluded unplanned treatments in their EFS definition,
which we could not do because of limitations of our data.
Finally, in this study, a limited number of patients were
treated with BEACOPP, a treatment not used in the British
Columbia series.19 A recent meta-analysis of clinical trials
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FIG 2. Estimated 5-year relapse risk
conditional on reaching event free
survival milestones. The x-axis repre-
sents the event-free survival (EFS)
milestone reached, and the y-axis
shows the estimated risk of a relapse
in the 5 years from the EFS milestone
onward. eg, In all patients, the 5-year
relapse probability measured from di-
agnosis onward was 10%. The 5-year
relapse risk of patients who reached
2 years of EFS was 3.6% and decreased
to 1.2% for patients who reached
5 years of EFS. (A) The 5-year relapse
risk estimates were calculated and
stratified by (B) age at diagnosis, (C)
stage, (D) calendar period of diagnostic
year, and (E) sex, (F) treatment for
advanced stage patients (six to eight
cycles of doxorubicin, bleomycin, vin-
blastine, and dacarbazine [ABVD] or
bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procar-
bazine, and prednisone [BEACOPP]).
Limited-stage was defined as Ann Arbor
stage I or IIA; advanced stage, as Ann
Arbor stage IIB, III, or IV.
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suggests a greatly reduced relapse risk as well as im-
proved OS (although with limited follow-up time) for pa-
tients with advanced-stage disease who begin treatment
with BEACOPP.33
Of particular interest for patients and relatives is that our
results and those of similar population-based studies18,19,27
show a very lowmortality and relapse risk for young patients
with cHL who are treated with contemporary treatments.
This information is helpful for patients from a psychological
perspective, and it allows them to plan their futures. Our
study also included 301 patients treated with BEACOPP,
which was established as one of the standard therapies
for advanced-stage cHL after the results of the HD9 and
HD11 trials.34-36 Although patient numbers are limited in
this study, the results are in line with previous reports that
showed the superior efficacy of BEACOPP on progression-
free survival/EFS: relapse risks were similar for patients with
advanced-stage disease treated with BEACOPP and ABVD
in our series despite more high-risk features in the BEA-
COPP subgroup.
Results about relapse risk for patients in ongoing remission
are relevant not only to patients but also to physicians who
manage cHL. Most patients respond to first-line chemo-
therapy and achieve complete remission, so there is a
clinical need for relevant survivorship care. Many patients
are routinely observed for several years in outpatient clinics,
where detection of preclinical relapses and late toxicities is
the focus. Survivorship programs are focusing more on
screening for serious late toxicities in HL, such as sec-
ondary breast cancer and lung cancer37,38 and cardio-
vascular disease, as well as the impact on quality of life (eg,
the impact of fatigue and sexual dysfunction).39,40 Our data
support the concept that rational cHL survivorship pro-
grams should focus mainly on appropriate management of
late toxicities rather than on screening for preclinical re-
lapse in patients in complete remission. In particular, ac-
tively screening for relapse after EFS24 does not seem cost
effective, because 5-year relapse risk is reduced to less
than 5% for nearly all young patients with cHL. This is also
supported by data that show that preclinical relapse de-
tection using serial CT scans does not improve outcomes
and that the majority of patients who experience relapse
typically present with clinical symptoms outside pre-
planned visits.41-45
Advanced stage, ABVD 6-8
Advanced stage, BEACOPP 6-8
2006-2013
2000-2005
35 to 49 years old
18 to 34 years old
Female
Male
Advanced stage
Limited stage
All patients
0 25 50 75 100
5-Year Restricted Loss in Expectation of Lifetime (days)
All at diagnosis
EFS12
EFS24
EFS60
Ch
ar
ac
te
ris
tic
FIG 3. Estimated 5-year restricted
loss of expectation of lifetime for all
patients and conditional on reaching
12, 24, or 60 months event-free
survival (EFS12, EFS24, and EFS60,
respectively). The 5-year restricted
loss of expectation of lifetime esti-
mates were calculated stratified by
stage, sex, age at diagnosis, calen-
dar period of diagnostic year, and
treatment for advanced stage pa-
tients (six to eight cycles of doxo-
rubicin, bleomycin, vinblastine, and
dacarbazine [ABVD] or bleomycin,
etoposide, doxorubicin, cyclophos-
phamide, vincristine, procarbazine,
and prednisone [BEACOPP]). Limited-
stage was defined as Ann Arbor
stage I or IIA; advanced stage, as
Ann Arbor stage IIB, III, or IV.
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FIG 4. Estimated 5-year relapse risk
conditional on reaching event-free sur-
vival (EFS) milestones obtained from a
multivariable model that included sex,
diagnosis year, age, and stage effects.
The x-axis represents the EFS milestone
reached, and the y-axis shows the esti-
mated risk of a progression or relapse in
the 5 years from the EFS milestone on-
ward. Limited-stage was defined as Ann
Arbor stage I or IIA; advanced-stage, as
Ann Arbor stage IIB, III, or IV.
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A strength of this study is the use of data from three
population-based registers that implemented measures to
safeguard against missing information. However, we can-
not exclude that a limited number of relapses were missed,
because we did not perform dedicated health record review
for this study. By use of register data, some of the usual
limitations of clinical trials, such as short follow-up4,46 and
high levels of patient selection,47 were avoided. Given the
large number of patients, analyses stratified by different
clinical subgroups were possible. By focusing on patients
diagnosed after the year 2000, we minimized the influence
of outdated treatments, in particular extended-field RT and
obsolete chemotherapy regimens. Although we consider
the inclusion of patients treated with BEACOPP a strength
of this study, the lack of random assignment between ABVD
and BEACOPP could result in confounding, so these results
should be interpreted with that in mind. Furthermore, the
reported analyses only describe the survival and relapse
risk, since we have no information on detrimental effects
of cHL on health-related quality of life, such as fatigue or
sexual and psychosocial health.48 A final caveat of this
study is that the median follow-up of 9 years, although
long compared with clinical trials, does not enable us
to evaluate the very long-term effects of contemporary
treatments.
With the use of 5-year relapse risks and loss of life ex-
pectancy measures, we provide estimates of the prognosis
conditioned on specific clinical characteristics and years in
remission for patients with cHL who received contemporary
treatments. The results are reassuring and indicate that
patients with limited-stage disease who remain event free at
2 years after diagnosis have a future life expectancy close to
that of HL-free individuals. In addition, in the majority of risk
groups, the 5-year relapse risk was minimal after 2 years of
EFS were reached, and this information should be con-
sidered when survivorship programs are planned.
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FIG 5. Estimated 5-year restricted loss of expectation of lifetime for all patients, and conditional on reaching 1-, 2-, or
5-year event-free survival (EFS12, EFS24, EFS60, respectively) obtained from amultivariable model that included sex,
diagnosis year, calendar period of diagnostic year, age, and stage effects. Limited-stage was defined as Ann Arbor
stage I or IIA; advanced stage, Ann Arbor stage IIB, III, or IV.
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